Ishita Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹3.03 crore and net profit of ₹0.16 crore for the September 2026 quarter.
Ishita Drugs (BSE: ISHITADR) closed at ₹74.01 on 20 Nov 2026, up 5.7% over the past year. Its market capitalisation is ₹22 crore and it trades at 30.3 times earnings.
Incorporated in 1992, Ishita Drugs & Industries Ltd is engaged in the manufacturing of various APIs and drug intermediates
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.